ArticleAdvanced healthcare materials2026
Multifunctional Catechol-Functionalized Cellulose Hydrogels for the Minimally Invasive Treatment of Acute Optic Nerve Injuries.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oxidative stress-induced retinal ganglion cell degeneration is a major pathological feature of acute optic nerve injury, yet current posterior-segment therapies are limited by poor local retention and repeated invasive administration. Here, we developed an injectable catechol-functionalized carboxymethyl cellulose hydrogel, CMCDA, as a bioadhesive and antioxidative intravitreal platform. Through dopamine grafting and oxidative crosslinking, CMCDA exhibited shear-thinning injectability, self-healing behavior, wet-tissue adhesion, controlled biodegradability, and good biocompatibility. In an optic nerve crush model, CMCDA significantly reduced retinal reactive oxygen species (ROS) accumulation, preserved retinal ganglion cells, promoted axonal regeneration, and attenuated microglial activation, with 7 wt% CMCDA showing the strongest therapeutic efficacy. Single-cell RNA sequencing further suggested that CMCDA reshaped the injured retinal microenvironment by suppressing apoptotic, oxidative-stress, and inflammatory pathways while supporting phototransduction-related programs. Importantly, these structural and molecular benefits were accompanied by improved visual function, as confirmed by visual cliff testing and electroretinography. Overall, CMCDA represents a multifunctional cellulose-based hydrogel platform for minimally invasive antioxidative neuroprotection, axonal repair, and functional recovery after optic nerve injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.